{
  "abstract": "Lynch syndrome (LS)-associated upper tract urothelial cancer (UTUC) is an overall rare malignancy comprising only 5%–10% of all urothelial carcinomas. Given its rarity, specific management guidelines for LS-associated UTUC do not exist. The optimal peri-operative management of localised LS-UTUC remains unknown, and with future approvals, immunotherapy may allow for organ preservation. This report describes a case of localised LS-UTUC with prior history of stage I colon cancer. An initial attempt to obtain an insurance approval for pembrolizumab given LS and context of deficient mismatch repair was unsuccessful. She subsequently received neoadjuvant gemcitabine and split-dose cisplatin, leading to a complete pathological response, ypT0N0.",
  "authors": [
    {
      "affiliations": [
        "Hematology Oncology, University of Illinois Chicago, Chicago, Illinois, USA"
      ],
      "name": "Lucia Notardonato"
    },
    {
      "affiliations": [
        "Hematology Oncology, University of Illinois Chicago, Chicago, Illinois, USA"
      ],
      "name": "Ahsan Wahab"
    },
    {
      "affiliations": [
        "Hematology Oncology, University of Illinois Chicago, Chicago, Illinois, USA"
      ],
      "name": "Natalie Reizine"
    },
    {
      "affiliations": [
        "Hematology Oncology, University of Illinois Chicago, Chicago, Illinois, USA"
      ],
      "name": "Karine Tawagi"
    }
  ],
  "title": "Peri-operative management considerations for localised upper tract urothelial carcinoma in the setting of Lynch syndrome",
  "uid": "6eef8c5c-fb4f-5c12-8070-63d4917296a6"
}